Company intelligence / Profile preview
POINT Biopharma
Indianapolis, Indiana, United Statespoint-biopharma.webflow.io ↗
- Ownership
- Public · PNT
- Development stage
- Commercial
01
Overview
POINT Biopharma developed a pipeline of radioligand therapies targeting various cancers. Its lead asset, 177Lu-PNT2003 targeting SSTR2 for neuroendocrine tumors, reached Phase 3. Other programs include FAP-targeted agents in early clinical development and PSMA-targeted therapies in preclinical stages. The company was acquired by Eli Lilly in December 2023 to expand Lilly’s oncology portfolio into next-generation radioligand therapies[5][4].
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalRadioligand therapySmall moleculePeptide conjugate radionuclide
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Athebio AG – collaboration on DARPin-targeted radioligands (“Radio-DARPins”)Strategic partnerships for radio-isotope supply and manufacturing technology
04
Financials
- Market cap
- $1.3B
- Total revenue
- $2.8M
- Enterprise value
- $1B
Beyond the preview
Go deeper on POINT Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POINT Biopharma.